A Study of MVA85A in Healthy Infants

Inclusion Criteria: 1. Age of 126 through 182 days on the day of randomization (Study Day 0) 2. Written informed consent obtained from the parents/guardian 3. Weight: by chart \>3rd percentile on Study Day 0 or, if \< 3rd percentile, infant has shown a stable growth pattern 4. BCG vaccination within 7 days of birth 5. Generally good health confirmed by medical history and physical examination within 35 days prior to Study Day 0 6. Must have received age-appropriate doses of pneumococcal vaccine as recommended by the South African Department of Health but no injection within 14 day prior to Study Day 0 7. Ability to complete follow-up period as required by the protocol 8. Completed simultaneous enrollment in the Aeras Vaccine Development Registry protocol Exclusion Criteria: 1. Acute illness on Study Day 0 2. Fever \>=37.5 degrees Celsius on Study Day 0 3. Evidence of significant active infection on Study Day 0 4. Received a Expanded Program of Immunization (EPI) within 14 days prior to Study Day 0 5. Historical or virological evidence of individual or maternal human immunodeficiency virus (HIV-1) infection 6. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine 7. Previous medical history, or evidence, of an intercurrent illness that may compromise the safety of the infant in the study 8. Evidence of chronic hepatitis from any cause 9. History or evidence of any systemic disease on physical examination or any acute, chronic or intercurrent illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine 10. History of or known tuberculosis or treatment for tuberculosis 11. Shared residence since birth with an individual with active tuberculosis or on anti-tuberculosis treatment for less than 2 months